Should You Buy GlaxoSmithKline plc, Diploma PLC & Merlin Entertainments PLC?

Are these 3 stocks ripe for investment? GlaxoSmithKline plc (LON: GSK), Diploma PLC (LON: DPLM) and Merlin Entertainments PLC (LON: MERL)

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

For many investors, the most appealing thing about GlaxoSmithKline (LSE: GSK) is its dividend yield. That’s because it stands at over 6%, which is over 200 basis points higher than the FTSE 100‘s yield of just under 4%. As such, the company’s income appeal is significant even though dividends are set to flat line over the next couple of years.

A reason for a lack of strong dividend growth moving forward is, of course, a change in strategy which is seeing GlaxoSmithKline implement a major overhaul to its cost base and to the structure of its business, although it has stopped short of spinning off its lucrative HIV treatment subsidiary ViiV Health Care. This restructuring should allow the company to become more efficient and focus on its product pipeline, which is among the most diversified and most appealing in the industry, with it having the potential to significantly boost GlaxoSmithKline’s profitability over the medium to long term.

Due in part to such major changes as well as poor investor sentiment resulting from pressure on sales in recent years from generic treatments, GlaxoSmithKline trades on a forward price to earnings (P/E) ratio of just 15.5. This indicates upward rerating potential – especially as investors continue to be nervous regarding the future prospects for the wider economy. As such, and while GlaxoSmithKline is a top notch yield play, it also has value and growth appeal, too.

Technical products producer Diploma (LSE: DPLM) is up 15% today after releasing an upbeat set of full-year results. Pretax profit increased by 4% even though currency headwinds led to a softening of sales in the second half of the year. In fact, Diploma’s acquisitions made a real difference to its performance and it believes that a more favourable environment for acquisitions could lead to improved results in future.

Looking ahead, Diploma is forecast to increase its bottom line by just 3% in the current year and, with its shares trading on a P/E ratio of 17.7, it appears to be fully valued. Clearly, a well-covered yield of 2.7% has some appeal, although on a relative basis there appear to be more enticing opportunities available elsewhere.

Meanwhile, theme park operator Merlin (LSE: MERL) has had a rather disappointing year, with its shares falling by 2% year-to-date. A key reason for this is the 1% fall in earnings which is forecast for the current year and which appears to have dampened investor sentiment in recent months.

Next year, though, Merlin is expected to post a rise in its bottom line of 15% and this puts it on a price to earnings growth (PEG) ratio of only 1.3. With its geographically diversified operations and range of attractions, it appears to be well-placed to cope with a potential downturn in the wider economy. And, with there being few (if any) stocks operating in the same space which are also listed on the FTSE 350, Merlin could prove to be a sound diversifier for Foolish investors over the coming years.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

UK investors are piling into Vodafone! Should I buy this FTSE 100 stock?

This ultra-cheap FTSE 100 dividend stock has been very popular among retail investors lately. What might they be seeing in…

Read more »

Market Movers

This FTSE 250 value stock is up 11% today! Here’s what’s going on

Jon Smith explains why a FTSE 250 stalwart is shooting higher today on fresh news and talks through why this…

Read more »

Inflation in newspapers
Investing Articles

£276bn worth of reasons to invest in UK shares?

Our writer prefers investing in UK shares to holding cash. However, he acknowledges that this approach does carry some risks.

Read more »

Investing Articles

Here’s the latest growth and share price forecasts for Nvidia stock

Nvidia is due to report Q4 results towards the end of February. Should I buy the stock in anticipation of…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Is the party over for the S&P 500 as Trump’s tariffs loom?

Donald Trump's planned tariffs have cast doubts on the future performance of the S&P 500. What should investors do now?

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Warren Buffett continues to invest in this well-known pizza company

Warren Buffett just bought another 1.1m shares in Domino’s Pizza. Should investors follow him into the well-known fast food company…

Read more »

Investing Articles

A £100 weekly income from a Stocks and Shares ISA? It’s possible!

Mark Hartley details how a combination of good stock picks and patience could transform a Stocks and Shares ISA into…

Read more »

Young black colleagues high-fiving each other at work
US Stock

Why Apple stock could be set to soar with the new Alibaba partnership

Jon Smith explains why a new deal relating to the Chinese market could be good news for Apple stock, not…

Read more »